ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Cardiovascular Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1618157
This article is part of the Research TopicMolecular Biomarkers of Cardiometabolic Disease - Volume IIView all 17 articles
Association of The Atherogenic Index of Plasma and high-sensitivity C-reactive protein with Incident Cardiovascular Disease: Evidence from a National Cohort of Middle-Aged and Older Chinese Adults
Provisionally accepted- 1Seventh people's hospital of Zhengzhou, Zhengzhou, China
- 2Henan Academy of Innovations in Medical Science, zhengzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The AIP and hs-CRP are both implicated in the development of CVD. However, their joint impact on CVD risk and the underlying mediation mechanisms remain unclear.This study used data from the CHARLS, including 8,763 adults aged ≥45 years with up to 9 years of follow-up. Multivariable Cox models assessed associations with CVD. Mediation analyses examined direct and indirect effects, including bidirectional mediation. Additive interaction was evaluated using the RERI, and predictive performance was assessed via ROC curve analysis.A total of 1,693 participants developed CVD during the follow-up period. Higher levels of AIP and hs-CRP were independently associated with CVD. Joint analysis showed that, compared with individuals with AIP below the median and hs-CRP <1 mg/L, those with elevated levels of both AIP and hs-CRP had the highest risks of CVD (HR: 1.655; 95% CI: 1.455-1.883), heart disease (HR:1.402; 95% CI: 1.207-1.628), and stroke (HR: 2.207; 95% CI: 1.771-2.749). These associations remained significant after adjustment for potential confounders, although the effect sizes were attenuated. Notably, the effect of hs-CRP on increased CVD risk was more pronounced among individuals with higher AIP levels. Mediation analysis revealed that hs-CRP mediated 6.6% of the association between AIP and CVD (P=0.042), while AIP mediated 20.3% of the association in the reverse pathway (P=0.008). The RERI between AIP and hs-CRP for CVD was 0.141 (95% CI: -0.102 to 0.384), suggesting a possible positive additive interaction. The ROC analysis indicated that the combined model had better predictive performance for CVD than either marker alone (AUC = 0.590), with the best performance observed in stroke prediction (AUC = 0.615). Subgroup analyses confirmed consistent associations across demographic and clinical subgroups, except in individuals with prediabetes or diabetes.Elevated levels of AIP and hs-CRP were independently and jointly associated with an increased risk of cardiovascular disease, particularly stroke. The observed mutual mediation effects and potential additive interaction suggest that lipid metabolism and inflammation may be interconnected in the pathophysiological processes underlying cardiovascular risk. These findings highlight the potential value of incorporating both biomarkers into cardiovascular risk assessment models to enhance early identification and prevention strategies among middle-aged and older adults.
Keywords: Atherogenic index of plasma, C-Reactive Protein, cardiovascular disease, Inflammation, longitudinal cohort study, CHARLS
Received: 25 Apr 2025; Accepted: 17 Jul 2025.
Copyright: © 2025 Lian, Xie, Zhang, Cheng, Zhao, Li, Liang, Zhu, Zhang, Cui, Du, Yin and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Shenwei Zhang, Seventh people's hospital of Zhengzhou, Zhengzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.